Conditions: Choroidal Neovascularization Macular Edema Glaucoma, Neovascular Diabetic Retinopathy
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 270
Healthy volunteers: no

Brief summary:
The pupose of this study is to evaluate the safety and the efficacy of ranibizumab in rare VEGF driven ocular diseases.

Detailed description:

Arms:
arm 1: 0.5 mg ranibizumab applied in an individualized regimen as IVT injection of 0.05 mL.

Interventions: intervention 1: ranibizumab
Intervention descriptions: intervention 1: One injection of Ranibizumab 0.5 mg and retreatment according to disease activity and/or visual impairment on an as needed regimen (PRN)

Protocol document: